Gilead Sciences (GILD) Set to Post Quarterly Earnings on Thursday

Key Points

• Gilead Sciences is scheduled to report Q3 2026 earnings after the market closes on October 29, with analysts expecting $2.18 in earnings per share and $7.79 billion in revenue.
• The company’s previous quarter exceeded expectations, posting $7.80 billion in revenue—up 10.6% year over year—and beating the consensus EPS estimate despite reporting a loss.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $159.63; Gilead also pays a quarterly dividend of $0.82 per share, representing a 2.1% yield.

Gilead Sciences (NASDAQ:GILD - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $2.18 per share and revenue of $7.79 billion for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 earnings per share. On average, analysts expect Gilead Sciences to post ($0.47) EPS for the current fiscal year and $9.91 EPS for the next fiscal year.

Gilead Sciences Trading Down 1.9%

Gilead Sciences stock opened at $153.57 on Thursday. Gilead Sciences has a 1 year low of $114.02 and a 1 year high of $160.51. The firm's 50 day moving average price is $148.36 and its 200-day moving average price is $137.60. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market cap of $190.42 billion, a P/E ratio of -57.52 and a beta of 0.31.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock worth $15,877,860 in the last three months. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Zacks Research downgraded shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 29th. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Bank of America increased their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a "buy" rating in a report on Tuesday. Weiss Ratings upgraded Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, September 14th. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $160.00 to $170.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $159.63.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.